Sun Pharmaceutical Industries Ltd. has said that it has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.
The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed.
Commenting on the development, Dilip Shanghvi, Managing Director, Sun Pharma said, “This is an important development for Sun Pharma. We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our manufacturing facilities globally.”
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Meanwhile, shares of the company were trading at Rs 559.45 apiece up 3.51 per cent from the previous close at 09:32 hrs on BSE.